Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.

PubWeight™: 1.20‹?› | Rank: Top 10%

🔗 View Article (PMID 18293383)

Published in Pediatr Blood Cancer on July 01, 2008

Authors

John M Maris1, Joshua Courtright, Peter J Houghton, Christopher L Morton, E Anders Kolb, Richard Lock, Mayamin Tajbakhsh, C Patrick Reynolds, Stephen T Keir, Jianrong Wu, Malcolm A Smith

Author Affiliations

1: Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA. maris@chop.edu

Articles citing this

Myc proteins as therapeutic targets. Oncogene (2010) 1.88

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47

Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol (2012) 1.22

A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib. Elife (2015) 1.20

Atypical teratoid/rhabdoid tumors in adults: a case report and treatment-focused review. J Clin Med Res (2011) 1.18

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res (2011) 1.10

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03

Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One (2012) 0.99

Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist (2011) 0.96

Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer (2010) 0.95

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol (2013) 0.95

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther (2016) 0.91

Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 0.90

Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr Oncol Rep (2008) 0.88

HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts. J Pediatr Surg (2013) 0.85

Targeted therapies for bone sarcomas. Bonekey Rep (2013) 0.85

Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs (2010) 0.83

Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma. Int J Mol Sci (2016) 0.82

Bone sarcomas: from biology to targeted therapies. Sarcoma (2012) 0.82

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). BMC Cancer (2015) 0.81

Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth. J Pathol (2010) 0.81

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol (2015) 0.80

Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell Int (2011) 0.80

Biologically targeted therapeutics in pediatric brain tumors. Pediatr Neurol (2012) 0.80

Targeting angiogenesis in childhood sarcomas. Sarcoma (2010) 0.77

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer (2014) 0.77

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia (2016) 0.76

Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst (2014) 0.76

Pediatric Osteosarcoma: An Updated Review. Indian J Med Paediatr Oncol (2017) 0.75

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res (2016) 0.75

Articles by these authors

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01

The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02

The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34

Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12

The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res (2009) 4.53

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood (2010) 3.66

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38

Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol (2005) 3.36

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood (2004) 3.13

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99

Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92

The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood (2009) 2.86

The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59

Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2.54

Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther (2007) 2.35

Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol (2012) 2.32

Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31

mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27

Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 2.25

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol (2013) 2.25

Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24

Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol (2006) 2.21

Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12

Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol (2003) 2.05

The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma. Pediatr Blood Cancer (2015) 1.97

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med (2011) 1.96

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.95

Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res (2004) 1.93

Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer (2007) 1.93

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91

Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91

IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88

Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell (2003) 1.84

Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res (2005) 1.83

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79

A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74

The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood (2002) 1.74

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71

Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res (2007) 1.71

E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res (2007) 1.70

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66

Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66

Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res (2003) 1.63

Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem (2002) 1.61

Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol (2007) 1.61

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res (2006) 1.58

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol (2010) 1.57

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.55